RGD-4C

• UNSPSC Description:

  RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models[1][2][3].

• Target Antigen:

  Integrin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rgd-4c.html

• Purity:

  99.82

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(N[C@@H](CSSC[C@@H](C(N[C@H]1CC(O)=O)=O)NC([C@@H](N)C)=O)C(NCC(O)=O)=O)[C@@H](NC([C@@](CSSC[C@](C(N[C@H]2CCCNC(N)=N)=O)([H])NC1=O)([H])NC([C@@H](NC(CNC2=O)=O)CC(O)=O)=O)=O)CC3=CC=CC=C3

• Molecular Weight:

  1145.27

• References & Citations:

  [1]Assa-Munt N, et al. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry. 2001 Feb 27;40(8):2373-8. |[2]Yin R, et al. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide. Bioconjug Chem. 2010 Jul 21;21(7):1142-7. |[3]Zuppone S, et al. A Novel RGD-4C-Saporin Conjugate Inhibits Tumor Growth in Mouse Models of Bladder Cancer. Front Oncol. 2022 Apr 11;12:846958.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  332179-76-7